{"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.772","statisticalComment":"crossover ANOVA of log-transformed data","statisticalMethod":"ANOVA"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"139","value":"307"},{"groupId":"OG001","spread":"262","value":"364"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"12"}],"units":"Participants"}],"description":"Vz/F was defined as the apparent volume of distribution.","dispersionType":"Standard Deviation","groups":[{"description":"Participants self-administered intermittent or continuous pemigatinib 13.5 mg QD in the fasted state in Part 2. Intermittent dosing: participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. Continuous dosing: participants self-administered oral pemigatinib 13.5 mg QD on Days 1 through 21 of each 21-day cycle.","id":"OG000","title":"Part 2: Intermittent/Continuous Pemigatinib 13.5 mg QD, Fasted"},{"description":"Participants self-administered intermittent or continuous pemigatinib 13.5 mg QD in the fed state in Part 2. Intermittent dosing: participants self-administered oral pemigatinib 13.5 mg QD on a 2-weeks-on therapy and 1-week-off therapy schedule. The treatment cycle consisted of: Days 1 through 14: pemigatinib QD; Days 15 through 21: treatment break. Continuous dosing: participants self-administered oral pemigatinib 13.5 mg QD on Days 1 through 21 of each 21-day cycle.","id":"OG001","title":"Part 2: Intermittent/Continuous Pemigatinib 13.5 mg QD, Fed"}],"paramType":"MEAN","populationDescription":"PK/PD Population. Only participants who participated in the food-effect study in Part 2 were analyzed.","reportingStatus":"POSTED","timeFrame":"Cycles 1 and 2: predose and 0.5, 1, 2, 4, 6, and 8 hours post-dose on Day 14","title":"Parts 1 and 2: Vz/F Steady State Following Administration of Pemigatinib in the Fasted (Cycle 1 Day 14) and Fed (Cycle 2 Day 14) States","type":"SECONDARY","unitOfMeasure":"Liters"}